GlassScriptPhysician profile
Kayvaan Mortazavi
NPI 1124265285
$3,968.60
in general payments reported to CMS, 2019-2025
33 companies · $1,941 in 2025
The $1,941 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,027 · 2025: $1,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,968.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $681.84 | 2024-2025 | Airsupra, Breztri, Byetta |
| Abbvie INC. | $500.32 | 2024-2025 | |
| Glaxosmithkline, LLC. | $442.97 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $418.05 | 2024-2025 | |
| Amgen INC. | $335.41 | 2024-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $239.35 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Radius Health, INC. | $130.15 | 2024-2025 | Tymlos |
| Novo Nordisk INC | $124.93 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $124.83 | 2024-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $93.42 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Aimmune Therapeutics, INC. | $75.36 | 2024-2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $74.17 | 2024-2025 | |
| Corcept Therapeutics | $73.55 | 2024 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.17 | 2024-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $63.99 | 2024-2025 | Voquezna |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $57.98 | 2024 | Veozah |
| Recordati_rare_diseases_inc. | $53.56 | 2024-2025 | Isturisa, Signifor Lar |
| Eisai INC. | $48.69 | 2024 | |
| Exact Sciences Corporation | $48.20 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.43 | 2025 | Caplyta |
| Dexcom, INC. | $30.99 | 2024 | Dexcom G6 Transmitter |
| Almatica Pharma LLC | $30.34 | 2024 | Teriparatide |
| Ascendis Pharma Endocrinology INC | $25.57 | 2024 | |
| Nevro Corp. | $23.35 | 2024 | Senza |
| Sanofi-Aventis U.S. LLC | $22.51 | 2024 | |
| Insulet Corporation | $20.52 | 2024 | Omnipod |
| Averitas Pharma INC. | $19.16 | 2025 | Qutenza |
| Antares Pharma, INC. | $18.52 | 2024 | Xyosted |
| Lundbeck LLC | $18.25 | 2024 | Rexulti |
| Amneal Pharmaceuticals LLC | $17.35 | 2025 | Unithroid |
| Amphastar Pharmaceuticals, INC. | $17.33 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.46 | 2025 | Jardiance |
| Evoke Pharma, INC. | $14.88 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayvaan Mortazavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.